Literature DB >> 23084587

Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.

Han Suk Ryu1, Jin-Haeng Chung, Kyoungbun Lee, Eun Shin, Jin Jing, Gheeyoung Choe, Haeryoung Kim, Xianhua Xu, Hee Eun Lee, Dae-Ghon Kim, Hyebin Lee, Ja-June Jang.   

Abstract

Although increased evidence has suggested that epithelial-mesenchymal transition has been implicated in cancer invasion and is associated with poor prognosis, its significance in cholangiocarcinoma remains unclear. We evaluated the levels of expression of epithelial-mesenchymal transition-related genes and proteins in 2 established human cholangiocarcinoma cell lines with different morphological characteristics and performed transwell cell invasion assays. Furthermore, we investigated the association between altered expression of 6 epithelial-mesenchymal transition-related proteins and clinical outcomes in human cholangiocarcinoma patients (n = 119) by immunohistochemistry using a tissue microarray approach. Comparative analysis of protein and messenger RNA expression revealed that the cell line with less differentiation (JCK) showed increased expression of mesenchymal markers and zinc-finger proteins and decreased expression of epithelial markers. The invasion activity of JCK cells was significantly higher than that of cells from OZ cell lines. Tissue microarray analysis revealed that the combined expression pattern of 6 epithelial-mesenchymal transition-related proteins predicted shortened disease-free survival (13.0 versus 22.0 months, P = .033) and overall survival (23.0 versus 63.0 months, P = .003) and was confirmed as an independent unfavorable prognostic factor for survival in multivariate survival analysis (disease-free survival, P = .028 for the 3 epithelial-mesenchymal transition-related markers; overall survival, P = .010 for the 6 epithelial-mesenchymal transition-related markers). In conclusion, our results suggest that altered expression of a number of epithelial-mesenchymal transition-related genes in tumor cells with poor differentiation may explain their increased invasive ability. Our results also suggest that altered expression of a suite of epithelial-mesenchymal transition-related proteins could be used as a tool to predict poor outcomes in human cholangiocarcinoma patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084587     DOI: 10.1016/j.humpath.2012.07.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  Prognostic value of multiple epithelial mesenchymal transition-associated proteins in intrahepatic cholangiocarcinoma.

Authors:  Xiangguo Tian; Zhixin Cao; Qian Ding; Zhen Li; Chunqing Zhang
Journal:  Oncol Lett       Date:  2019-06-24       Impact factor: 2.967

2.  SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.

Authors:  Min-Sun Jin; Chang Lim Hyun; In Ae Park; Ji Young Kim; Yul Ri Chung; Seock-Ah Im; Kyung-Hun Lee; Hyeong-Gon Moon; Han Suk Ryu
Journal:  Tumour Biol       Date:  2015-10-30

3.  Prognostic Nomogram That Predicts Overall Survival of Patients with Distal Cholangiocarcinoma After Pancreatoduodenectomy.

Authors:  Qiao Chen; Jiayi Li; Bao Jin; Xiangan Wu; Yue Shi; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Cancer Manag Res       Date:  2020-10-20       Impact factor: 3.989

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 5.  Epithelial to Mesenchymal Transition in a Clinical Perspective.

Authors:  Jennifer Pasquier; Nadine Abu-Kaoud; Haya Al Thani; Arash Rafii
Journal:  J Oncol       Date:  2015-09-06       Impact factor: 4.375

6.  Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.

Authors:  Z Yu; H Cheng; H Zhu; M Cao; C Lu; S Bao; Y Pan; Y Li
Journal:  Braz J Med Biol Res       Date:  2017-08-17       Impact factor: 2.590

Review 7.  Context-dependent EMT programs in cancer metastasis.

Authors:  Nicole M Aiello; Yibin Kang
Journal:  J Exp Med       Date:  2019-04-11       Impact factor: 14.307

8.  BRAF Mutation in Colorectal Rhabdoid and Poorly Differentiated Medullary Carcinomas.

Authors:  Elena Bolzacchini; Nunzio Digiacomo; Cristina Marrazzo; Nora Sahnane; Roberta Maragliano; Anthony Gill; Luca Albarello; Fausto Sessa; Daniela Furlan; Carlo Capella
Journal:  Cancers (Basel)       Date:  2019-08-26       Impact factor: 6.639

9.  Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.

Authors:  Cheng-Zong Li; Yu-Xiang Lin; Tian-Cong Huang; Jun-Yong Pan; Gao-Xiong Wang
Journal:  Onco Targets Ther       Date:  2019-11-01       Impact factor: 4.147

10.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.